Complex of Amino Acids, Choline, and B-Group Vitamins for the Improvement of Early-Stage Metabolic Dysfunction-Associated Steatotic Liver Disease — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Complex of Amino Acids, Choline, and B-Group Vitamins for the Improvement of Early-Stage Metabolic Dysfunction-Associated Steatotic Liver Disease
Faculty of Medicine and Life Sciences, University of Latvia, Riga, Latvia
,
Faculty of Medicine, Riga Stradins University, Riga, Latvia
,
Olivia Clinic, Riga, Latvia
,
Faculty of Medicine and Life Sciences, University of Latvia, Riga, Latvia
,
Center of Gastroenterology, Hepatology and Nutrition, Pauls Stradins Clinical University Hospital, Riga, Latvia
1 Faculty of Medicine and Life Sciences, University of Latvia, Riga, Latvia
2 Faculty of Medicine, Riga Stradins University, Riga, Latvia
3 Olivia Clinic, Riga, Latvia
4 Faculty of Medicine and Life Sciences, University of Latvia, Riga, Latvia
5 Center of Gastroenterology, Hepatology and Nutrition, Pauls Stradins Clinical University Hospital, Riga, Latvia
Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the most common cause of chronic liver disease worldwide, affecting an estimated 25% of the global population. Up to 80% of individuals with hepatic steatosis remain asymptomatic and may show no biochemical abnormalities, meaning that MASLD is frequently silent until complications occur, which makes early diagnosis challenging. Lifestyle modification, including dietary changes, regular physical activity, and sustained weight reduction, is the cornerstone of MASLD management. At present, however, there is still no universally standardized pharmacological treatment for MASLD all over the world, and management continues to rely primarily on lifestyle modification. The amino acids and B-group vitamin complex is expected to be effective in treating the early stage of steatohepatosis and steatohepatitis, reducing aminotransferases levels and decreasing liver fat cell accumulation.
KeywordsMASLDMASHAmino AcidsB-Group Vitamins
Rinella, M.E., et al. (2023) A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature. Hepatology , 78, 1966-1986.
Rinella, M.E. and Sookoian, S. (2024) From NAFLD to MASLD: Updated Naming and Diagnosis Criteria for Fatty Liver Disease. Journal of Lipid Research , 65, Article ID: 100485. https://doi.org/10.1016/j.jlr.2023.100485
Li, J., Zou, B., Yeo, Y.H., Feng, Y., Xie, X., Lee, D.H., et al. (2019) Prevalence, Incidence, and Outcome of Non-Alcoholic Fatty Liver Disease in Asia, 1999-2019: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology & Hepatology , 4, 389-398. https://doi.org/10.1016/s2468-1253(19)30039-1
Hydes, T., Alam, U. and Cuthbertson, D.J. (2021) The Impact of Macronutrient Intake on Non-Alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories? Frontiers in Nutrition , 8, Article 640557. https://doi.org/10.3389/fnut.2021.640557
Li, Y., Yang, P., Ye, J., Xu, Q., Wu, J. and Wang, Y. (2024) Updated Mechanisms of MASLD Pathogenesis. Lipids in Health and Disease , 23, Article No. 117. https://doi.org/10.1186/s12944-024-02108-x
Wang, D., Xu, Y., Zhu, Z., Li, Y., Li, X., Li, Y., et al. (2022) Changes in the Global, Regional, and National Burdens of NAFLD from 1990 to 2019: A Systematic Analysis of the Global Burden of Disease Study 2019. Frontiers in Nutrition , 9, Article 1047129. https://doi.org/10.3389/fnut.2022.1047129
Huang, D.Q., Singal, A.G., Kono, Y., Tan, D.J.H., El-Serag, H.B. and Loomba, R. (2022) Changing Global Epidemiology of Liver Cancer from 2010 to 2019: NASH Is the Fastest Growing Cause of Liver Cancer. Cell Metabolism , 34, 969-977.e2. https://doi.org/10.1016/j.cmet.2022.05.003
Ge, X., Zheng, L., Wang, M., Du, Y. and Jiang, J. (2020) Prevalence Trends in Non-Alcoholic Fatty Liver Disease at the Global, Regional and National Levels, 1990-2017: A Population-Based Observational Study. BMJ Open , 10, e036663. https://doi.org/10.1136/bmjopen-2019-036663
Wang, T., George, J. and Zheng, M. (2021) Metabolic (Dysfunction) Associated Fatty Liver Disease: More Evidence and a Bright Future. Hepatobiliary Surgery and Nutrition , 10, 849-852. https://doi.org/10.21037/hbsn-21-352
Quek, J., Chan, K.E., Wong, Z.Y., Tan, C., Tan, B., Lim, W.H., et al. (2023) Global Prevalence of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in the Overweight and Obese Population: A Systematic Review and Meta-analysis. The Lancet Gastroenterology & Hepatology , 8, 20-30. https://doi.org/10.1016/s2468-1253(22)00317-x
Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., et al. (2005) Design and Validation of a Histological Scoring System for Nonalcoholic Fatty Liver Disease. Hepatology , 41, 1313-1321. https://doi.org/10.1002/hep.20701
Siddiqui, M.S., Harrison, S.A., Abdelmalek, M.F., Anstee, Q.M., Bedossa, P., Castera, L., et al. (2018) Case Definitions for Inclusion and Analysis of Endpoints in Clinical Trials for Nonalcoholic Steatohepatitis through the Lens of Regulatory Science. Hepatology , 67, 2001-2012. https://doi.org/10.1002/hep.29607
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EA-SO) (2016) EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Obesity Facts , 9, 65-90. https://doi.org/10.1159/000443344
Wong, V.W., Chan, W., Chitturi, S., Chawla, Y., Dan, Y.Y., Duseja, A., et al. (2017) Asia-Pacific Working Party on Non-Alcoholic Fatty Liver Disease Guidelines 2017—Part 1: Definition, Risk Factors and Assessment. Journal of Gastroenterology and Hepatology , 33, 70-85. https://doi.org/10.1111/jgh.13857
Chalasani, N., Younossi, Z., Lavine, J.E., Charlton, M., Cusi, K., Rinella, M., et al. (2017) The Diagnosis and Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. Hepatology , 67, 328-357. https://doi.org/10.1002/hep.29367
Zatloukal, K., French, S.W., Stumptner, C., Strnad, P., Harada, M., Toivola, D.M., et al. (2007) From Mallory to Mallory-Denk Bodies: What, How and Why? Experimental Cell Research , 313, 2033-2049. https://doi.org/10.1016/j.yexcr.2007.04.024
Brown, G.T. and Kleiner, D.E. (2016) Histopathology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Metabolism , 65, 1080-1086. https://doi.org/10.1016/j.metabol.2015.11.008
Radu, F., Potcovaru, C., Salmen, T., Filip, P.V., Pop, C. and Fierbințeanu-Braticievici, C. (2023) The Link between NAFLD and Metabolic Syndrome. Diagnostics , 13, Article 614. https://doi.org/10.3390/diagnostics13040614
Ioannou, G.N. (2021) Epidemiology and Risk-Stratification of NAFLD-Associated HCC. Journal of Hepatology , 75, 1476-1484. https://doi.org/10.1016/j.jhep.2021.08.012
Cataldo, I., Sarcognato, S., Sacchi, D., Cacciatore, M., Baciorri, F., Mangia, A., et al. (2021) Pathology of Non-Alcoholic Fatty Liver Disease. Pathologica , 113, 194-202. https://doi.org/10.32074/1591-951x-242
Eslam, M., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology , 73, 202-209.
Eslam, M., Sanyal, A.J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., et al. (2020) MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology , 158, 1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312
Monelli, F., Venturelli, F., Bonilauri, L., Manicardi, E., Manicardi, V., Rossi, P.G., et al. (2021) Systematic Review of Existing Guidelines for NAFLD Assessment. Hepatoma Research , 7, Article 25. https://doi.org/10.20517/2394-5079.2021.03
Wong, V.W., Adams, L.A., de Lédinghen, V., Wong, G.L. and Sookoian, S. (2018) Noninvasive Biomarkers in NAFLD and NASH—Current Progress and Future Promise. Nature Reviews Gastroenterology & Hepatology , 15, 461-478. https://doi.org/10.1038/s41575-018-0014-9
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., et al. (2024) EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Journal of Hepatology , 81, 492-542. https://doi.org/10.1016/j.jhep.2024.04.031
Taylor, R.S., Taylor, R.J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J.M., et al. (2020) Association between Fibrosis Stage and Outcomes of Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterology , 158, 1611-1625.e12. https://doi.org/10.1053/j.gastro.2020.01.043
Wong, V.W., Tak, W.Y., Goh, G.B.B., Cheng, P., Lawitz, E.J., Younossi, Z.M., et al. (2023) Performance of Noninvasive Tests of Fibrosis among Asians, Hispanic, and Non-Hispanic Whites in the STELLAR Trials. Clinical Gastroenterology and Hepatology , 21, 90-102.e6. https://doi.org/10.1016/j.cgh.2022.01.015
Wong, V.W.S., Zelber-Sagi, S., Cusi, K., Carrieri, P., Wright, E., Crespo, J., et al. (2022) Management of NAFLD in Primary Care Settings. Liver International , 42, 2377-2389. https://doi.org/10.1111/liv.15404
Kaswala, D.H., Lai, M. and Afdhal, N.H. (2016) Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Digestive Diseases and Sciences , 61, 1356-1364. https://doi.org/10.1007/s10620-016-4079-4
Romero-Gómez, M., Zelber-Sagi, S. and Trenell, M. (2017) Treatment of NAFLD with Diet, Physical Activity and Exercise. Journal of Hepatology , 67, 829-846. https://doi.org/10.1016/j.jhep.2017.05.016
American Diabetes Association (2018) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019. Diabetes Care , 42, S90-S102. https://doi.org/10.2337/dc19-s009
Raschi, E., Mazzotti, A., Poluzzi, E., De Ponti, F. and Marchesini, G. (2018) Pharmacotherapy of Type 2 Diabetes in Patients with Chronic Liver Disease: Focus on Nonalcoholic Fatty Liver Disease. Expert Opinion on Pharmacotherapy , 19, 1903-1914. https://doi.org/10.1080/14656566.2018.1531126
Mantovani, A., Byrne, C.D., Scorletti, E., Mantzoros, C.S. and Targher, G. (2020) Efficacy and Safety of Anti-Hyperglycaemic Drugs in Patients with Non-Alcoholic Fatty Liver Disease with or without Diabetes: An Updated Systematic Review of Randomized Controlled Trials. Diabetes & Metabolism , 46, 427-441. https://doi.org/10.1016/j.diabet.2019.12.007
Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T.J., Sunny, N.E., et al. (2019) Impact of Exenatide on Mitochondrial Lipid Metabolism in Mice with Nonalcoholic Steatohepatitis. Journal of Endocrinology , 241, 293-305. https://doi.org/10.1530/joe-19-0007
Rinella, M.E., Neuschwander-Tetri, B.A., Siddiqui, M.S., Abdelmalek, M.F., Caldwell, S., Barb, D., et al. (2023) AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology , 77, 1797-1835. https://doi.org/10.1097/hep.0000000000000323
He, W., Xu, Y., Ren, X., Xiang, D., Lei, K., Zhang, C., et al. (2019) Vitamin E Ameliorates Lipid Metabolism in Mice with Nonalcoholic Fatty Liver Disease via Nrf2/CES1 Signaling Pathway. Digestive Diseases and Sciences , 64, 3182-3191. https://doi.org/10.1007/s10620-019-05657-9
Uchida, D., Takaki, A., Adachi, T. and Okada, H. (2018) Beneficial and Paradoxical Roles of Anti-Oxidative Nutritional Support for Non-Alcoholic Fatty Liver Disease. Nutrients , 10, Article 977. https://doi.org/10.3390/nu10080977
Butterworth, R.F. and Canbay, A. (2018) Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. Digestive Diseases , 37, 63-68. https://doi.org/10.1159/000491429
Voloshin, I., Hahn-Obercyger, M., Anavi, S. and Tirosh, O. (2014) L-Arginine Conjugates of Bile Acids-a Possible Treatment for Non-Alcoholic Fatty Liver Disease. Li pids in Health and Disease , 13, Article No. 69. https://doi.org/10.1186/1476-511x-13-69
Canbay, A., Götze, O., Kucukoglu, O., Weinert, S., Croner, R.S., Baars, T., et al. (2024) L-Ornithine-L-Aspartate (LOLA) Normalizes Metabolic Parameters in Models of Steatosis, Insulin Resistance and Metabolic Syndrome. Pharmaceutics , 16, Article 506. https://doi.org/10.3390/pharmaceutics16040506
Kircheis, G. and Lüth, S. (2019) Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy. Drugs , 79, 23-29. https://doi.org/10.1007/s40265-018-1023-2
Oleshchuk, O.M., et al. (2021) Hepatoprotective Effects of L-Ornithine-L-Aspartate in Toxic Liver Injury. Pharmacology Online , 3, 146-155.
Hadi, A., Arab, A., Moradi, S., Pantovic, A., Clark, C.C.T. and Ghaedi, E. (2019) The Effect of L-Arginine Supplementation on Lipid Profile: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. British Journal of Nutrition , 122, 1021-1032. https://doi.org/10.1017/s0007114519001855
Wu, G., Meininger, C.J., McNeal, C.J., Bazer, F.W. and Rhoads, J.M. (2021) Role of L-Arginine in Nitric Oxide Synthesis and Health in Humans. In: Wu, G., Ed., Amino Acids in Nutrition and Health , Springer, 167-187. https://doi.org/10.1007/978-3-030-74180-8_10
Stach, K., Stach, W. and Augoff, K. (2021) Vitamin B6 in Health and Disease. Nutrients , 13, Article 3229. https://doi.org/10.3390/nu13093229
Wang, J., Zhang, C., Zhang, Z., Chen, Q., Lu, X., Shao, M., et al. (2014) BL153 Partially Prevents High-Fat Diet Induced Liver Damage Probably via Inhibition of Lipid Accumulation, Inflammation, and Oxidative Stress. Oxidative Medicine and Cellular Longevity , 2014, Article ID: 674690. https://doi.org/10.1155/2014/674690
Liu, Z., Zeng, Y., Shen, S., Wen, Y. and Xu, C. (2023) Association between Folate and Non-Alcoholic Fatty Liver Disease among US Adults: A Nationwide Cross-Sectional Analysis. Chinese Medical Journal , 136, 233-235. https://doi.org/10.1097/cm9.0000000000002516
Chan, C., Chan, P. and Lin, B. (2022) Folate Deficiency Increased Lipid Accumulation and Leptin Production of Adipocytes. Frontiers in Nutrition , 9, Article 852451. https://doi.org/10.3389/fnut.2022.852451
Tripathi, M., Singh, B.K., Zhou, J., Tikno, K., Widjaja, A., Sandireddy, R., et al. (2022) Vitamin B12 and Folate Decrease Inflammation and Fibrosis in NASH by Preventing Syntaxin 17 Homocysteinylation. Journal of Hepatology , 77, 1246-1255. https://doi.org/10.1016/j.jhep.2022.06.033
Molaqanbari, M.R., Zarringol, S., Talari, H.R., Taghizadeh, M., Bahmani, F., Mohtashamian, A., et al. (2023) Effects of Folic Acid Supplementation on Liver Enzymes, Lipid Profile, and Insulin Resistance in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Advanced Biomedical Research , 12, 103. https://doi.org/10.4103/abr.abr_90_22
Abe, R.A.M., Masroor, A., Khorochkov, A., Prieto, J., Singh, K.B., Nnadozie, M.C., et al. (2021) The Role of Vitamins in Non-Alcoholic Fatty Liver Disease: A Systematic Review. Cureus , 13, e16855. https://doi.org/10.7759/cureus.16855
Koplay, M., Gulcan, E. and Ozkan, F. (2011) Association between Serum Vitamin B12 Levels and the Degree of Steatosis in Patients with Nonalcoholic Fatty Liver Disease. Journal of Investigative Medicine , 59, 1137-1140. https://doi.org/10.2310/jim.0b013e31822a29f5
Talari, H.R., Molaqanbari, M.R., Mokfi, M., Taghizadeh, M., Bahmani, F., Tabatabaei, S.M.H., et al. (2022) The Effects of Vitamin B12 Supplementation on Metabolic Profile of Patients with Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial. Scientific Reports , 12, Article No. 14047. https://doi.org/10.1038/s41598-022-18195-8
Lonardo, A., Nascimbeni, F., Ballestri, S., Fairweather, D., Win, S., Than, T.A., et al. (2019) Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps. Hepatology , 70, 1457-1469. https://doi.org/10.1002/hep.30626
Polyzos, S.A., Kountouras, J. and Mantzoros, C.S. (2019) Obesity and Nonalcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics. Metabolism , 92, 82-97. https://doi.org/10.1016/j.metabol.2018.11.014
Pang, Q. (2015) Central Obesity and Nonalcoholic Fatty Liver Disease Risk after Adjusting for Body Mass Index. World Journal of Gastroenterology , 21, 1650-1662. https://doi.org/10.3748/wjg.v21.i5.1650
Reis, S.S., Callejas, G.H., Marques, R.A., Gestic, M.A., Utrini, M.P., Chaim, F.D.M., et al. (2021) Correlation between Anthropometric Measurements and Non-Alcoholic Fatty Liver Disease in Individuals with Obesity Undergoing Bariatric Surgery: Cross-Sectional Study. Obesity Surgery , 31, 3675-3685. https://doi.org/10.1007/s11695-021-05470-2
Xing, J., Guan, X., Zhang, Q., Chen, S., Wu, S. and Sun, X. (2021) Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study. Obesity Facts , 14, 190-196. https://doi.org/10.1159/000514848
Minciuna, I., Taru, M., Fodor, A., Nicoara Farcau, O., Fischer, P., Radu, C., et al. (2024) Multiparametric Ultrasound Evaluation of Liver Fibrosis, Steatosis, and Viscosity in Patients with Chronic Liver Disease. Medical Ultrasonography , 26, 117-124. https://doi.org/10.11152/mu-4327
Baldini, F., Khalil, M., Bartolozzi, A., Vassalli, M., Di Ciaula, A., Portincasa, P., et al. (2022) Relationship between Liver Stiffness and Steatosis in Obesity Conditions: In Vivo and in Vitro Studies. Biomolecules , 12, Article 733. https://doi.org/10.3390/biom12050733
Fujii, I., Matsumoto, N., Ogawa, M., Konishi, A., Kaneko, M., Watanabe, Y., et al. (2024) Artificial Intelligence and Image Analysis-Assisted Diagnosis for Fibrosis Stage of Metabolic Dysfunction-Associated Steatotic Liver Disease Using Ultrasonography: A Pilot Study. Diagnostics , 14, Article 2585. https://doi.org/10.3390/diagnostics14222585